Date: 2016-06-01
Type of information: R&D agreement
Compound: CAR-Treg-based cellular immunotherapy
Company: Txcell (France) Lübeck Institute of Experimental Dermatology (LIED) (Germany)
Therapeutic area: Autoimmune diseases - Dermatological diseases - Rare diseases
Type agreement: R&D
Action mechanism: immunotherapy product/cell therapy/gene therapy
Disease: bullous pemphigoid (BP)
Details: * On June 1st, 2016, TxCell announced a strategic R&D collaboration agreement with the Lübeck Institute of Experimental Dermatology (LIED), a leading institution in the field of translational research on skin blistering diseases, part of the University of Lübeck in Germany. This agreement covers the development of a CAR-Treg-based cellular immunotherapy for bullous pemphigoid, a rare, potentially fatal autoimmune disease characterized by tense inflammatory skin blisters and in some patients, erosions on mucous membranes. TxCell scientists have already identified a relevant antigenic target for the development of a CAR-Treg product in bullous pemphigoid patients. The CAR construct will be designed to ensure the activation of CAR-Treg cells specifically in the inflammatory skin lesions. TxCell and LIED will conduct non-clinical pharmacology studies with CAR-Treg cells to prepare for a first in-man study in bullous pemphigoid patients. The collaboration will involve two LIED teams: the Model Systems of Inflammatory Skin Diseases team led by Prof. Ralf Ludwig and the Translational Research team led by Prof. Enno Schmidt.
Financial terms: TxCell retains all rights on existing and future programs and products developed under this agreement. Financial terms of the collaboration have not been disclosed.
Latest news:
